Amgen 3Q Revenues: $6.4 billion (+12%) 3Q Earnings: $2.0 billion (+3%) YTD Revenues: $18.8 billion (+9%) YTD Earnings: $5.6 billion (-8%) Comments: Product sales increased 12% globally, driven by 18% volume growth across a number of our newer products, including Otezla, MVASI, KANJINTI, and Repatha, partially offset by declines in select products from the impact of COVID-19, and biosimilar and generic competition. Prolia sales increased 11% to $701 million. EVENITY generated ...